−2.25USD
−73.62 MUSD
8.36 MUSD
28.86 M
About Molecular Partners AG
Sector
Industry
CEO
Patrick Amstutz
Website
Headquarters
Schlieren
Employees (FY)
182
Founded
2004
ISIN
CH0256379097
FIGI
BBG00L53GM78
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of MLLCF is 3.80 USD — it has decreased by 7.32% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Molecular Partners AG stocks are traded under the ticker MLLCF.
Molecular Partners AG is going to release the next earnings report on May 16, 2024. Keep track of upcoming events with our Earnings Calendar.
MLLCF stock is 7.89% volatile and has beta coefficient of 0.44. Check out the list of the most volatile stocks — is Molecular Partners AG there?
One year price forecast for Molecular Partners AG has a max estimate of 16.43 USD and a min estimate of 3.29 USD.
MLLCF earnings for the last quarter are −0.61 USD per share, whereas the estimation was −0.77 USD resulting in a 20.83% surprise. The estimated earnings for the next quarter are −0.59 USD per share. See more details about Molecular Partners AG earnings.
Molecular Partners AG revenue for the last quarter amounts to 2.73 M USD despite the estimated figure of 1.53 M USD. In the next quarter revenue is expected to reach 475.10 K USD.
Yes, you can track Molecular Partners AG financials in yearly and quarterly reports right on TradingView.
MLLCF stock has fallen by 7.32% compared to the previous week, the month change is a 7.32% fall, over the last year Molecular Partners AG has showed a 30.78% decrease.
MLLCF net income for the last quarter is −23.49 M USD, while the quarter before that showed −12.49 M USD of net income which accounts for −88.03% change. Track more Molecular Partners AG financial stats to get the full picture.
Today Molecular Partners AG has the market capitalization of 120.64 M, it has decreased by 3.20% over the last week.
No, MLLCF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, MLLCF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Molecular Partners AG stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 182.00 employees. See our rating of the largest employees — is Molecular Partners AG on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Molecular Partners AG technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Molecular Partners AG stock shows the sell signal. See more of Molecular Partners AG technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Molecular Partners AG future price: according to them, MLLCF price has a max estimate of 16.43 USD and a min estimate of 3.29 USD. Read a more detailed Molecular Partners AG forecast: see what analysts think of Molecular Partners AG and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Molecular Partners AG EBITDA is −69.71 M USD, and current EBITDA margin is −833.87%. See more stats in Molecular Partners AG financial statements.